- Home
- DAKT vs FBIOP Comparison
DAKT vs FBIOP Comparison
Compare DAKT & FBIOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAKT
- FBIOP
- Stock Information
- Founded
- DAKT 1968
- FBIOP N/A
- Country
- DAKT United States
- FBIOP United States
- Employees
- DAKT N/A
- FBIOP 101
- Industry
- DAKT Office Equipment/Supplies/Services
- FBIOP Biotechnology: Pharmaceutical Preparations
- Sector
- DAKT Industrials
- FBIOP Health Care
- Exchange
- DAKT Nasdaq
- FBIOP Nasdaq
- Market Cap
- DAKT N/A
- FBIOP N/A
- IPO Year
- DAKT 1994
- FBIOP N/A
- Fundamental
- Price
- DAKT $12.46
- FBIOP $6.74
- Analyst Decision
- DAKT Strong Buy
- FBIOP
- Analyst Count
- DAKT 1
- FBIOP 0
- Target Price
- DAKT $26.00
- FBIOP N/A
- AVG Volume (30 Days)
- DAKT 456.0K
- FBIOP N/A
- Earning Date
- DAKT 03-05-2025
- FBIOP N/A
- Dividend Yield
- DAKT N/A
- FBIOP N/A
- EPS Growth
- DAKT N/A
- FBIOP N/A
- EPS
- DAKT 0.04
- FBIOP N/A
- Revenue
- DAKT $799,806,000.00
- FBIOP N/A
- Revenue This Year
- DAKT N/A
- FBIOP N/A
- Revenue Next Year
- DAKT $4.86
- FBIOP N/A
- P/E Ratio
- DAKT $311.56
- FBIOP N/A
- Revenue Growth
- DAKT N/A
- FBIOP N/A
- 52 Week Low
- DAKT $9.22
- FBIOP N/A
- 52 Week High
- DAKT $19.89
- FBIOP N/A
- Technical
- Relative Strength Index (RSI)
- DAKT 48.60
- FBIOP 67.87
- Support Level
- DAKT $11.97
- FBIOP $6.00
- Resistance Level
- DAKT $12.80
- FBIOP $6.80
- Average True Range (ATR)
- DAKT 0.62
- FBIOP 0.42
- MACD
- DAKT 0.11
- FBIOP 0.16
- Stochastic Oscillator
- DAKT 75.12
- FBIOP 96.19
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.